BetterInvesting Magazine Update on Stride Inc.  and Amgen Inc.

BetterInvesting Magazine Update on Stride Inc. and Amgen Inc.

Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here .

A full report on Stride will appear in the August 2025 issue of BetterInvesting Magazine.

The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.

Committee members are Daniel J. Boyle , CFA; Marisa Bradbury , CFA; Philip Keating , CFA; Walter J. Kirchberger , CFA; Anne Nichols , CFA; and Dan Rutter , CFA.

Doron P. Levin , an editor of the magazine, serves as the committee's chairperson.

Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn , Instagram and Facebook .

Contact: 877-275-6242

Cision View original content: https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-stride-inc-nyse-lrn-and-amgen-inc-nasdaq-amgn-302466516.html

SOURCE NAIC-BetterInvesting

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Releases Second Episode of Investor Video Series

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, a... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer

BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components... Keep Reading...
Lexaria Updates Progress on Human Study #7

Lexaria Updates Progress on Human Study #7

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema")... Keep Reading...
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
Lexaria Bioscience (NASDAQ:LEXX)

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...

Interactive Chart

Latest Press Releases

Related News